- Home
- CBFV vs AARD Comparison
CBFV vs AARD Comparison
Compare CBFV & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CBFV | AARD |
|---|---|---|
| Founded | 1901 | 2017 |
| Country | United States | United States |
| Employees | 174 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.9M | 165.8M |
| IPO Year | 2014 | 2025 |
Fundamental Metrics
Financial Performance| Metric | CBFV | AARD |
|---|---|---|
| Price | $37.25 | $6.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $38.00 | $15.29 |
| AVG Volume (30 Days) | 2.9K | ★ 120.3K |
| Earning Date | 04-22-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.12% | N/A |
| EPS Growth | N/A | ★ 43.11 |
| EPS | ★ 1.54 | N/A |
| Revenue | ★ $43,557,000.00 | N/A |
| Revenue This Year | $48.93 | N/A |
| Revenue Next Year | $7.97 | N/A |
| P/E Ratio | $24.27 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $30.97 | $3.35 |
| 52 Week High | $38.86 | $17.94 |
Technical Indicators
Market Signals| Indicator | CBFV | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 50.49 | 53.15 |
| Support Level | $33.75 | $5.12 |
| Resistance Level | $37.79 | $8.02 |
| Average True Range (ATR) | 0.37 | 0.88 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 26.04 | 59.50 |
Price Performance
Historical ComparisonAbout CBFV CB Financial Services Inc.
CB Financial Services Incis a bank holding company headquartered in Carmichaels, Pennsylvania. The company had one reportable segment, community banking services. The Bank also has a loan production office in Allegheny County, a loan production office and a corporate center in Washington County, and an operations center in Greene County, Pennsylvania. The Bank is a community-oriented institution offering residential and commercial real estate loans, commercial and industrial loans, and consumer loans, as well as a variety of deposit products for individuals and businesses in its market area.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.